SANTA MONICA, Calif., June 05, 2020 (GLOBE NEWSWIRE) — Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmaceuticals Industries Ltd. Opiant’s commercial partner Emergent BioSolutions, intends to appeal the decision to the Court of Appeals for the Federal Circuit.
News Ticker
- [ December 9, 2023 ] Product Release Coordinator- QA Pharmaceutical / Biotech – Full Time Days – Grifols – Los Angeles, CA Los Angeles Biotech Jobs
- [ December 8, 2023 ] “Frozen” Composer Christophe Beck and Kristen Bell Reunite at Education Through Music-Los Angeles Gala Los Angeles Biotech News
- [ December 8, 2023 ] Medical Lab Scientist – Techsara solutions Inc – Mission Viejo, CA Los Angeles Biotech Jobs
- [ December 8, 2023 ] City of Hope Doctors and Scientists Present Innovative Research at Largest Gathering on Breast Cancer Research Los Angeles Biotech News
- [ December 8, 2023 ] UCLA researchers lay groundwork to study effects of maternal diabetes on fetal metabolism and development Featured News
Copyright © 2023 Biotech Networks, LLC
